Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer

[1]  Andrew R. Green,et al.  MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.

[2]  M. Ringnér,et al.  Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.

[3]  Mårten Fernö,et al.  The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer , 2010, Modern Pathology.

[4]  J. Cuzick,et al.  Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. , 2009 .

[5]  L. Holmberg,et al.  Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[6]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Axel Hausen,et al.  Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers , 2009, Breast Cancer Research and Treatment.

[8]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[9]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[10]  Patrick Royston,et al.  Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables , 2008 .

[11]  M. Gilcrease,et al.  Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12 155 Patients , 2008 .

[12]  T. Thalhammer,et al.  Cell Cycle Dysregulation Influences Survival in High Risk Breast Cancer Patients , 2008, Cancer investigation.

[13]  M. Dowsett,et al.  International Web-based consultation on priorities for translational breast cancer research , 2007, Breast Cancer Research.

[14]  H. Nevanlinna,et al.  Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut‐off values? , 2007, Histopathology.

[15]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[16]  C. Orlandini,et al.  Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients. , 2006, Anticancer research.

[17]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[18]  H. Nevanlinna,et al.  Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides , 2006, British Journal of Cancer.

[19]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[20]  J. Russo,et al.  Erratum: Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index (Modern Pathology (2005) 18 (1067-1078) DOI: 10.1038/modpathol.3800388) , 2005 .

[21]  C. Blomqvist,et al.  Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer , 2005, British Journal of Cancer.

[22]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[23]  Andrew Glass,et al.  Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index , 2005, Modern Pathology.

[24]  M. Fernö,et al.  "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. , 2004, European journal of cancer.

[25]  J. Baak,et al.  Prognostic value of proliferation in invasive breast cancer: a review , 2004, Journal of Clinical Pathology.

[26]  M. Fernö,et al.  Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node‐negative breast cancer , 2003, International journal of cancer.

[27]  M. Fernö,et al.  Expression of cyclins E, A, and B, and prognosis in lymph node‐negative breast cancer , 2003, The Journal of pathology.

[28]  P. V. van Diest,et al.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment , 2002, British Journal of Cancer.

[29]  J. Nesland,et al.  Over‐expression of cyclin a is highly associated with early relapse and reduced survival in patients with primary breast carcinomas , 2001, International journal of cancer.

[30]  N. Brünner,et al.  S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[32]  D. Schoenfeld,et al.  Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.

[33]  J. Russo,et al.  Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index , 2005, Modern Pathology.

[34]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.